Endocyte (original) (raw)
Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis.
| Property | Value |
|---|---|
| dbo:abstract | Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis. Endocyte is advancing the first technology platform for the creation of small molecule drug conjugates (a.k.a. SMDCs), which consist of a small molecule linked to a potent drug, and is developing a pipeline of SMDCs together with non-invasive companion imaging agents for cancer, inflammatory diseases and kidney disease (autosomal-dominant polycystic kidney disease/ADPKDor PKD). Endocyte’s lead drug candidate is vintafolide, an investigational targeted cancer therapeutic in late-stage development. In 2012 marketing rights were acquired by Merck for 120millioninanupfrontpaymentandupto120 million in an upfront payment and up to 120millioninanupfrontpaymentandupto880 million in milestone payments.Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is expressed on many cancers, such as ovarian cancer, and a potent chemotherapy drug, a derivative of vinblastine. Endocyte retained rights to the development and commercialization of etarfolatide. Endocyte’s other preclinical drug candidates also target the folate receptor as well as prostate-specific membrane antigen (PSMA) receptors. The company was formed based on technology developed by Philip Low (the company's CSO), and Christopher Leamon, PhD, the company’s VP of research. This technology is a folic acid-based drug delivery system, referred to now as folate targeting. The company is also developing SMDCs with varying drug payloads as well as different ligands for other molecular targets, such as prostate-specific membrane antigen (PSMA) and has also developed, with Bristol-Myers Squibb, an epothilone-folic acid conjugate (BMS-753493), described at a 2008 conference. In mid-October 2018, Novartis announced it would acquire Endocyte Inc for 2.1billion(2.1 billion (2.1billion(24 per share) merging it with a newly created subsidiary. Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate 177Lu-PSMA-617 being targeted against metastatic castration-resistant prostate cancer. (en) |
| dbo:foundingYear | 1996-01-01 (xsd:gYear) |
| dbo:industry | dbr:Biologic_medical_product |
| dbo:numberOfEmployees | 78 (xsd:nonNegativeInteger) |
| dbo:parentCompany | dbr:Novartis |
| dbo:type | dbr:Subsidiary |
| dbo:wikiPageExternalLink | https://www.endocyte.com |
| dbo:wikiPageID | 39669742 (xsd:integer) |
| dbo:wikiPageLength | 8679 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1082477862 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Purdue_Research_Park dbr:Epothilone dbc:1996_establishments_in_Indiana dbc:Pharmaceutical_companies_established_in_1996 dbr:Vinblastine dbr:Vintafolide dbr:NASDAQ dbc:West_Lafayette,_Indiana dbr:Chief_science_officer dbr:Bristol-Myers_Squibb dbc:2018_mergers_and_acquisitions dbc:2011_initial_public_offerings dbr:West_Lafayette,_Indiana dbr:Etarfolatide dbc:American_subsidiaries_of_foreign_companies dbr:Novartis dbc:Health_care_companies_based_in_Indiana dbr:Biologic_medical_product dbr:Folate_receptor dbr:Folate_targeting dbr:Glutamate_carboxypeptidase_II dbr:President_(corporate_title) dbc:Companies_formerly_listed_on_the_Nasdaq dbr:Subsidiary dbc:Pharmaceutical_companies_of_the_United_States dbr:Chief_Executive_Officer dbc:Novartis dbr:Initial_public_offering dbr:Merck_&_Co. dbr:Lutetium_(177Lu)_vipivotide_tetraxetan dbr:Small_molecule_drug_conjugate |
| dbp:homepage | https://www.endocyte.com |
| dbp:industry | dbr:Biologic_medical_product |
| dbp:keyPeople | Mike Sherman, (en) |
| dbp:locationCity | West Lafayette, Indiana (en) |
| dbp:locationCountry | United States (en) |
| dbp:name | Edocyte (en) Endocyte (en) |
| dbp:numEmployees | 78 (xsd:integer) |
| dbp:parent | dbr:Novartis |
| dbp:secCik | 1235007 (xsd:integer) |
| dbp:tradedAs | NASDAQ:ECYT (en) |
| dbp:type | dbr:Subsidiary |
| dbp:wikiPageUsesTemplate | dbt:As_of dbt:Authority_control dbt:Infobox_company dbt:Official dbt:Reflist dbt:Short_description dbt:Small dbt:Start_date dbt:Finance_links_historical |
| dct:subject | dbc:1996_establishments_in_Indiana dbc:Pharmaceutical_companies_established_in_1996 dbc:West_Lafayette,_Indiana dbc:2018_mergers_and_acquisitions dbc:2011_initial_public_offerings dbc:American_subsidiaries_of_foreign_companies dbc:Health_care_companies_based_in_Indiana dbc:Companies_formerly_listed_on_the_Nasdaq dbc:Pharmaceutical_companies_of_the_United_States dbc:Novartis |
| gold:hypernym | dbr:Company |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 yago:WikicatCompaniesBasedInIndiana yago:Abstraction100002137 yago:Company108058098 yago:DrugCompany108002578 yago:Group100031264 yago:Institution108053576 yago:Organization108008335 yago:YagoLegalActor yago:YagoLegalActorGeo yago:YagoPermanentlyLocatedEntity dbo:Organisation yago:SocialGroup107950920 yago:WikicatPharmaceuticalCompaniesOfTheUnitedStates |
| rdfs:comment | Endocyte (NASDAQ: ECYT) is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013, the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis. (en) |
| rdfs:label | Endocyte (en) |
| owl:sameAs | freebase:Endocyte yago-res:Endocyte wikidata:Endocyte https://global.dbpedia.org/id/fizN |
| skos:closeMatch | http://www.grid.ac/institutes/grid.421008.f |
| prov:wasDerivedFrom | wikipedia-en:Endocyte?oldid=1082477862&ns=0 |
| foaf:homepage | https://www.endocyte.com |
| foaf:isPrimaryTopicOf | wikipedia-en:Endocyte |
| foaf:name | Endocyte (en) |
| is dbo:wikiPageWikiLink of | dbr:Purdue_Research_Park dbr:David_Meek dbr:DMTHF-Tc dbr:Vintafolide dbr:Novartis dbr:Technetium_(99mTc)_etarfolatide dbr:Lutetium_(177Lu)_vipivotide_tetraxetan dbr:Small_molecule_drug_conjugate |
| is foaf:primaryTopic of | wikipedia-en:Endocyte |